Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront Combination Therapy for PAH
NCT01305252Phase 4Completed
- Sponsor
- Stanford University
- Start
- Jul 2010
- Primary completion
- Sep 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of treprostinil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Stanford University. Primary endpoint: Right Ventricular Ejection Fraction at 24 weeks. Started Jul 2010; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01305252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01305252.